Using AI, we identified publications that likely reported a testing or mutation rate, filtered publications for cancer type, and identified sentences that likely reported rates. Rates and covariates ...
A new report shows better than 80% concordance between liquid biopsy and tissue biopsy. Liquid biopsy and analysis of circulating tumor DNA (ctDNA) is a viable option for determining the presence of ...
The FDA approved FoundationOneCDx as the first companion diagnostic for current and future BRAF inhibitor therapeutics used to treat melanoma, including both monotherapies and combination therapies.
NEW YORK (Reuters) - Pfizer is trying to increase doctor awareness of and testing for a rare lung cancer mutation to help boost use of its drug Braftovi, which the pharmaceutical maker anticipates ...
A review article led by researchers from the B·ARGO group at the Germans Trias i Pujol Research Institute (IGTP) and from the Medical Oncology Department of the Catalan Institute of Oncology (ICO) in ...
Following the recent FDA approval of Braftovi with Mektovi for some patients with NSCLC and a BRAF V600E mutation, a lung cancer expert explains the science behind the news. The recent approval by the ...
In BREAKWATER, EC plus FOLFIRI achieved a 64.4% response rate and showed a trend toward improved overall survival in patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback